Graham R Foster

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi request reprint Hepatitis C virus infection: quality of life and side effects of treatment
    G R Foster
    The Liver Unit, Imperial College of Medicine at St Mary s, St Mary s Hospital, London, UK
    J Hepatol 31:250-4. 1999
  2. ncbi request reprint Past, present, and future hepatitis C treatments
    Graham R Foster
    Hepatobiliary Group, Department of Adult and Paediatric Gastroenterology, Queen Marys School of Medicine and Dentistry, London, United Kingdom
    Semin Liver Dis 24:97-104. 2004
  3. pmc Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases
    Amy D Brideau-Andersen
    Maxygen, Incorporated, 515 Galveston Drive, Redwood City, CA 94063, USA
    Proc Natl Acad Sci U S A 104:8269-74. 2007
  4. ncbi request reprint Therapeutic options for HCV--management of the infected individual
    G R Foster
    The Liver Centre, Imperial College School of Medicine at St Mary s Hospital, London, UK
    Baillieres Best Pract Res Clin Gastroenterol 14:255-64. 2000
  5. ncbi request reprint Human T cells elicit IFN-alpha secretion from dendritic cells following cell to cell interactions
    G R Foster
    Department of Medicine, ICSM, St Mary s Hospital, London, GB
    Eur J Immunol 30:3228-35. 2000
  6. ncbi request reprint Management of chronic hepatitis C--time for a change?
    Graham R Foster
    Imperial College Faculty of Medicine at St Mary s, St Mary s Hospital, Praed Street, London W2 1PG, UK
    J Viral Hepat 9:82-3. 2002
  7. doi request reprint Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b
    Graham R Foster
    Queen Mary University of London, The Liver Unit, Blizard Institute of Cellular and Molecular Science, Barts and the London School of Medicine, The Royal London Hospital, London, UK
    Drugs 70:147-65. 2010
  8. ncbi request reprint Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Graham R Foster
    The Royal London Hospital, London, UK
    Scand J Gastroenterol 42:247-55. 2007
  9. doi request reprint Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections
    Graham R Foster
    Queen Marys University of London, Blizard Institute of Cellular and Molecular Science, London, UK
    Gastroenterology 141:881-889.e1. 2011
  10. ncbi request reprint Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure
    Graham R Foster
    Queen Marys University of London, Institute of Cell and Molecular Science, London, UK
    J Hepatol 58:488-94. 2013

Collaborators

Detail Information

Publications32

  1. ncbi request reprint Hepatitis C virus infection: quality of life and side effects of treatment
    G R Foster
    The Liver Unit, Imperial College of Medicine at St Mary s, St Mary s Hospital, London, UK
    J Hepatol 31:250-4. 1999
    ....
  2. ncbi request reprint Past, present, and future hepatitis C treatments
    Graham R Foster
    Hepatobiliary Group, Department of Adult and Paediatric Gastroenterology, Queen Marys School of Medicine and Dentistry, London, United Kingdom
    Semin Liver Dis 24:97-104. 2004
    ....
  3. pmc Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases
    Amy D Brideau-Andersen
    Maxygen, Incorporated, 515 Galveston Drive, Redwood City, CA 94063, USA
    Proc Natl Acad Sci U S A 104:8269-74. 2007
    ....
  4. ncbi request reprint Therapeutic options for HCV--management of the infected individual
    G R Foster
    The Liver Centre, Imperial College School of Medicine at St Mary s Hospital, London, UK
    Baillieres Best Pract Res Clin Gastroenterol 14:255-64. 2000
    ..New therapies including polyethylene glycol, PEGylated, interferons and combination regimes involving amantadine are currently under evaluation and it is hoped that improved regimes will be developed in the near future...
  5. ncbi request reprint Human T cells elicit IFN-alpha secretion from dendritic cells following cell to cell interactions
    G R Foster
    Department of Medicine, ICSM, St Mary s Hospital, London, GB
    Eur J Immunol 30:3228-35. 2000
    ..Type I DC produce Type I IFN not only following viral infection but also during an immunological interaction and this may be the basic mechanism that assists in the development of a Th1 response...
  6. ncbi request reprint Management of chronic hepatitis C--time for a change?
    Graham R Foster
    Imperial College Faculty of Medicine at St Mary s, St Mary s Hospital, Praed Street, London W2 1PG, UK
    J Viral Hepat 9:82-3. 2002
  7. doi request reprint Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b
    Graham R Foster
    Queen Mary University of London, The Liver Unit, Blizard Institute of Cellular and Molecular Science, Barts and the London School of Medicine, The Royal London Hospital, London, UK
    Drugs 70:147-65. 2010
    ..Peginterferon plus ribavirin, as the standard of care for patients with chronic hepatitis C, may in the future form the basis of improved treatment regimens that include new, targeted anti-HCV agents to increase SVR rates even further...
  8. ncbi request reprint Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Graham R Foster
    The Royal London Hospital, London, UK
    Scand J Gastroenterol 42:247-55. 2007
    ..The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors...
  9. doi request reprint Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections
    Graham R Foster
    Queen Marys University of London, Blizard Institute of Cellular and Molecular Science, London, UK
    Gastroenterology 141:881-889.e1. 2011
    ..We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 2 or 3 infections...
  10. ncbi request reprint Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure
    Graham R Foster
    Queen Marys University of London, Institute of Cell and Molecular Science, London, UK
    J Hepatol 58:488-94. 2013
    ....
  11. doi request reprint Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse
    Dania Shoeb
    The Liver Unit, Blizard Institute for Cellular and Molecular Science, Queen Mary University of London, London, UK
    Eur J Gastroenterol Hepatol 23:747-53. 2011
    ..We completed a retrospective analysis of patients with genotype 3 hepatitis C virus (HCV) undergoing therapy in four UK centres with large populations of patients from the Indian subcontinent...
  12. ncbi request reprint Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus
    Graham R Foster
    Department of Adult and Paediatric Gastroenterology, The Royal London Hospital, Turner Street, London, E1 2AD, UK
    Expert Opin Pharmacother 4:685-91. 2003
    ..Their ease of administration, coupled with their improved efficacy, is likely to lead to an increase in the proportion of infected patients who wish to receive treatment...
  13. doi request reprint Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis
    Sudeep Tanwar
    Department of Medicine, Centre for Hepatology, University College London, London, UK
    Eur J Gastroenterol Hepatol 24:543-50. 2012
    ....
  14. doi request reprint Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?
    Graham R Foster
    Department of Hepatology, Queen Mary, University of London, London, UK
    Liver Int 32:61-3. 2012
    ..Those opposed to the 'lead-in' phase cite the complexity of the regime and the lack of robust evidence showing an improvement in clinical outcome in those treated in this fashion...
  15. pmc Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals
    Natasha K Martin
    School of Social and Community Medicine, University of Bristol, Bristol, UK Social and Mathematical Epidemiology Group, Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK
    Hepatology 58:1598-609. 2013
    ..Conclusion: Interferon-free DAAs could enable increased HCV treatment uptake among PWID, which could have a major preventative impact. However, treatment costs may limit scale-up, and should be addressed...
  16. pmc Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity
    Peter M George
    Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College, London, UK
    Pulm Circ 2:501-4. 2012
    ..This hypothesis can be easily tested in IFN-treated patients by measuring serum endothelin-1 levels and cardiopulmonary physiological parameters...
  17. doi request reprint Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis
    Ross J Harris
    Health Protection Agency Centre for Infections, London, UK
    Eur J Public Health 22:187-92. 2012
    ..We incorporate new information on HCV risk among non-injectors by ethnic group, and additional information on injecting prevalence in order to generate new and updated estimates of HCV prevalence risk in England for 2005...
  18. doi request reprint Managing diabetes in patients with chronic liver disease
    Roaid Khan
    Department of Diabetes and Metabolism, The Royal London Hospital, London, UK
    Postgrad Med 124:130-7. 2012
    ..Management of patients with diabetes and CLD may be enhanced by using a multidisciplinary approach...
  19. ncbi request reprint Advances in the diagnosis and treatment of hepatitis B
    William Alazawi
    The Liver Unit, Barts and the London School of Medicine, London, UK
    Curr Opin Infect Dis 21:508-15. 2008
    ..Although the armament of drugs licensed for its treatment grows, it is increasingly apparent that the efficacy of these drugs is dependent upon much more that their pharmacology...
  20. pmc Diagnosis and treatment of chronic hepatitis B
    Raymond D'Souza
    Digestive Disease Research Centre, Queen Mary s School of Medicine and Dentistry, Barts and The London NHS Trust, London, UK
    J R Soc Med 97:318-21. 2004
  21. ncbi request reprint Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease
    Daniel M Forton
    Hepatology Section, Division of Medicine A, Faculty of Medicine, Imperial College, St Mary s Hospital, London, UK
    Hepatology 35:433-9. 2002
    ..The findings on MRS suggest that a biological cause underlies this abnormality...
  22. ncbi request reprint Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C
    Anna Hollander
    Division of Infectious Diseases, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Scand J Gastroenterol 41:577-85. 2006
    ..To study the relationship between health-related quality of life (HRQOL) and mode of acquisition, treatment discontinuations, drop in haemoglobin levels and treatment outcome in patients with chronic hepatitis C (CHC)...
  23. pmc Diagnosis and treatment of hepatitis C
    Raymond D'Souza
    Digestive Disease Research Centre, Royal London Hospital, Turner Street, London E1 1BB, UK
    J R Soc Med 97:223-5. 2004
  24. ncbi request reprint High yield expression, refolding, and characterization of recombinant interferon alpha2/alpha8 hybrids in Escherichia coli
    Dimitris Platis
    Imperial College Faculty of Medicine at St Mary s Hospital, South Wharf Road, London W2 1NY, UK
    Protein Expr Purif 31:222-30. 2003
    ....
  25. ncbi request reprint Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta
    Dimitris Platis
    Imperial College Faculty of Medicine at St Mary s Hospital, London W2 1NY, England
    J Interferon Cytokine Res 23:655-66. 2003
    ..This suggests that this hybrid mimics the interactions of IFN-beta with the receptor and also suggests the existence of a distinct binding site(s) on IFNAR for IFN-beta and some hybrid IFN-alphas...
  26. ncbi request reprint Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials
    Alessandra Mangia
    Division of Gastroenterology, Ospedale Casa Sollievo Sofferenza, IRCCS, San Giovanni Rotondo 71013, Italy
    J Hepatol 40:478-83. 2004
    ..We performed a meta-analysis of the individual patient's data from previous studies...
  27. pmc Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression
    Meleri Jones
    DDRC, Queen Mary s School of Medicine and Dentistry, Royal Free and University College Medical School, Rowland Hill St, London NW3 2PF, United Kingdom
    J Virol 79:5414-20. 2005
    ..Collectively, these data show that dengue virus is capable of subverting the human IFN response by down-regulating STAT2 expression...
  28. ncbi request reprint The way forward in HCV treatment--finding the right path
    Michael P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany
    Nat Rev Drug Discov 6:991-1000. 2007
    ..Here we review the specific challenges posed by HCV, and recent developments in the design of vaccines and novel antiviral agents...
  29. ncbi request reprint Interferons at age 50: past, current and future impact on biomedicine
    Ernest C Borden
    Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Nat Rev Drug Discov 6:975-90. 2007
    ..Our goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential...
  30. ncbi request reprint IFN-alpha subtypes differentially affect human T cell motility
    Graham R Foster
    Hepatobiliary Group, Department of Gastroenterology, Queen Mary s School of Medicine and Dentistry at Barts and The Royal London Hospital, United Kingdom
    J Immunol 173:1663-70. 2004
    ..These observations are consistent with the possibility that subtype-specific intracellular signaling pathways are activated by type I IFNs in T lymphocytes...
  31. ncbi request reprint Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood
    Raymond D'Souza
    Hepatobiliary Group, Department of Adult and Pediatric Gastroenterology, Barts and The London, Queen Mary s School of Medicine and Dentistry, London, United Kingdom
    Clin Gastroenterol Hepatol 3:910-7. 2005
    ....
  32. pmc Chronic exposure to Helicobacter pylori impairs dendritic cell function and inhibits Th1 development
    Peter Mitchell
    Department of Immunology, Division of Medicine, Faculty of Medicine, Imperial College at Hammersmith Hospital, London, United Kingdom
    Infect Immun 75:810-9. 2007
    ..Our results raise the possibility that in chronic H. pylori infection DCs become exhausted after prolonged antigen exposure leading to suboptimal Th1 development. This effect may contribute to persistence of H. pylori infection...